Rockwell Medical, Inc.

As of August 13, 2025, Rockwell Medical, Inc. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -34.80% versus the S&P's 12.22%.

As of June 17, 2025, Rockwell Medical, Inc. is in a bearish trend with moderate strength, indicated by bearish daily moving averages, monthly MACD and RSI, and bearish Bollinger Bands across weekly and monthly time frames.

As of March 2022, the management team of Rockwell Medical, Inc. includes Mr. John McLaughlin (Independent Chairman), Dr. Russell Ellison (President and CEO), and Independent Directors Mr. John Cooper, Mr. Robert Radie, and Mr. Mark Ravich. They oversee the company's strategic direction and operations.

Rockwell Medical, Inc. is a biopharmaceutical company focused on treating end-stage renal disease and chronic kidney disease, with recent net sales of $19 million and a market cap of $31.23 million. The company is currently operating at a loss, with a net profit of -$2 million.

As of Jun 18, Rockwell Medical, Inc. has a market capitalization of 31.23 million and reported net sales of 97.72 million with a net profit of -0.56 million for the latest four quarters. Shareholder's funds were 32.59 million, and total assets were 59.21 million.